Imatinib Mesylate Causes Hypopigmentation in the Skin

Cancer

Volumn 98, Issue 11, 2003, Pages 2483-2487

  Tsao, Anne S ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   O'Brien, Susan ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelogenous leukemia (CML); Imatinib mesylate; Skin depigmentation, MAP kinase, microphthalmia

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; CYTARABINE; HYDROXYUREA; IMATINIB; RUBITECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; HYPOPIGMENTATION; LEG CRAMP; LEUKEMIA CELL; MALE; MOUTH SORE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; ORBIT DISEASE; PERIORBITAL EDEMA; PREDICTION; PRIORITY JOURNAL; REMISSION; SKIN DARKENING; SKIN DISEASE; SKIN ULCER; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

ADULT; AGED; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOPIGMENTATION; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PIPERAZINES; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 0344412948     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11812     Document Type: Article

References (10)

1. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
2. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy, N Engl J Med. 2002;346:683-693.
3. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis, J Invest Dermatol. 1998;111:233-238.
4. Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol. 1999;113:139-140.
5. Raanani P, Goldman JM, Ben-Bassat I. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. J Clin Oncol. 2002;20:869-870.
6. Nomura K, Hatayama I, Narita T, Kaneko T, Shiraishi M. A novel KIT gene missense mutation in a Japanese family with piebaldism. J Invest Dermatol. 1998;111:337-338.
7. Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44:288-292.
8. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301.
9. Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000;14:301-312.
10. Pagnoni A, Kligman AM, Sadiq I, Stoudemayer T. Hypopigmented macules of photodamaged skin and their treatment with topical tretinoin. Acta Derm Venereol. 1999;79:305-310.